Helix, the Silicon Valley company that’s styled itself as an app store for DNA tests, made a splash last week when it announced it had raised $200 million — the latest windfall for a company leveraging a boom in consumer genomics.
But as money sloshes around the industry, there’s an uneasy and unsettled question gnawing at even the most bullish investors: Are these bets going to pay off?
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Great reporting and a cool animated DNA/money graphic. You can look at it two ways: 1) money is “poring” into DTC genomics, or 2) investments are going down the well.